Comparative hepatic effectiveness of empagliflozin vs dapagliflozin among individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. (PubMed, Diabetologia) - Oct 1, 2026 - "Among individuals with MASLD, no significant differences were observed between empagliflozin and dapagliflozin in the risk of decompensated hepatic events."
Journal • Diabetes • Fibrosis • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Transplantation • Type 2 Diabetes Mellitus
|
|
Bin Hong; Christopher D Byrne; Hwa Yeon Ko; Jae Hyun Bae; Ju Hwan Kim; Ju-Young Shin; Sungho Bea; Suyeon Kim; Yoosoo Chang; Young Min Cho
|